Results 211 to 220 of about 5,097,893 (305)

RSF1‐Dependent PAR Turnover Promotes 53BP1 Liquid Condensate Formation at DNA Damage Sites

open access: yesAdvanced Science, EarlyView.
At sites of DNA damage, RSF1 recruits PARG to accelerate PAR turnover, triggering a switch from PAR‐driven condensates to 53BP1 condensates. This condensate transition enables p53‐dependent gene transcription and coordinates the DNA damage response.
Yungyeong Heo   +10 more
wiley   +1 more source

Compact 9dBEs Enable Efficient and Precise Genome Editing in Mammalian Cells and In Vivo

open access: yesAdvanced Science, EarlyView.
As a compact type II‐D system, the Cas9d‐based platform holds great potential for in vivo applications. Through rational engineering, its derived base editors (9dBEs) enable efficient disease modeling while facilitating single‐vector AAV delivery for in vivo genome editing. These miniature tools offer a robust strategy for basic research and biomedical
Qingquan Xiao   +12 more
wiley   +1 more source

Streptococcal Mannose Phosphotransferase System Component IID Is a Novel RANK‐Binding Osteoclastogenic Factor

open access: yesAdvanced Science, EarlyView.
Streptococcal mannose phosphotransferase system component IID (Man‐PTSIID) is identified as a novel RANK‐binding osteoclastogenic factor. By directly binding to RANK and activating NF‐κB independently of TLR2, Man‐PTSIID drives osteoclastogenesis and inflammatory bone destruction, uncovering an unexpected microbial mechanism underlying streptococcal ...
Chaeyeon Park   +13 more
wiley   +1 more source

Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy